Real World Psilocybin Outcomes

States

This dashboard shows aggregate, real-world outcomes from licensed psilocybin services at healing centers in Oregon and Colorado, updated in real time as facilitators and centers record sessions. All figures are aggregated across participants; no individual-level data is shown. See Methods & data notes for how this data is collected and what it can and cannot show.

Showing real-world data from January 2025 through November 2026.

Baseline Screening Scores

Wellness (WHO-5) Mean

13.1/ 25

n=4564

Anxiety (GAD-7) Mean

12.1/ 21

n=1506

Depression (PHQ-9) Mean

13.9/ 27

n=1203

Wellness (WHO-5) CHANGE

+3.0

n=1721

13.4 → 16.4

Anxiety (GAD-7) CHANGE

-6.3

n=517

11.8 → 5.5

Depression (PHQ-9) CHANGE

-7.1

n=422

13.6 → 6.5

Wellness (WHO-5): Pre vs Post

n = 1721 paired scores

Baseline
2-Week Post

Anxiety (GAD-7): Pre vs Post

n = 517 paired scores

Baseline
2-Week Post

Depression (PHQ-9): Pre vs Post

n = 422 paired scores

Baseline
2-Week Post

Pre-post comparisons use strict pairing: only participants with both a baseline and two-week post-journey score for the same instrument are included. GAD-7 and PHQ-9 are administered adaptively — they only appear when initial screening scores (GAD-2 ≥ 3 or PHQ-2 ≥ 3) indicate elevated symptoms, so fewer participants have paired scores for these instruments.

Mystical Experiences (MEQ-30)

MEQ-30 Mean Total

99.6/ 150

n=3434

Complete Mystical Experience Rate

65.8%

n=3434

2260 scored >= 90

Adverse Events

Category	Timing	Adverse Events	Sessions Reported	Rate
Behavioral	During Session	471 severe	5805	0.8%
Medical	During Session	573 severe	5807	1.0%
Behavioral	Post Session	14	2035	0.7%
Medical	Post Session	20	2038	1.0%

Severe events are a subset of the adverse event count, not additional to it.